RNS12 Oct 2020 08:22
Another research machine ordered!
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces the Company has received its latest research unit order for a 9820 Xenon Polariser system from the University of Texas MD Anderson Cancer Center ("MD Anderson Cancer Center").
MD Anderson Cancer Center is a major cancer research and teaching hospital. This new unit will initiate their research programme using hyperpolarised noble gas imaging in oncology, including assessing lung function as consequence of chemotherapy and radiation therapies, and providing guidance for improved radiation treatment planning, among other topics.
Richard Hullihen, CEO of Polarean, said: "We are excited to begin our relationship with MD Anderson Cancer Center who have pioneered such a breadth of oncology applications for medical imaging for this patient population, and welcome them to the group of our users researching the use of hyperpolarised 129 Xe in pulmonary function."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.